SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is actively discussed after its obesity drug's trial results did not match a key rival, leading to a significant stock dip; however, this is tempered by regulatory actions against unauthorized compounded GLP-1s and robust demand for its oral weight-loss treatment, causing a split in community sentiment between caution and buying the dip.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz following impressive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, coupled with strong financial reporting. This has led the community to discuss "disease modifying" potential and widespread anticipation of a substantial market re-rating and short covering ahead of its investor day.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of Bysanti (milsaperidone) with New Chemical Entity status and patent protection until 2044, igniting community speculation about a significant short squeeze and potential buyout offers from larger pharmaceutical firms. Investors are weighing the drug's long-term revenue potential against ongoing concerns of market manipulation and potential dilution.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending high following robust earnings and an optimistic 2026 outlook, reinforcing its leadership in the GLP-1 market, especially as a key competitor provided a weaker forecast. The community is also keenly watching its pipeline diversification through recent acquisitions and the anticipated launch of its oral weight-loss therapy.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention following news that Novo Nordisk's experimental obesity drug performed below Eli Lilly's in a Phase 3 trial, intensifying community discussions and expectations for Viking's own potentially best-in-class GLP-1/GIP assets to become a prime acquisition or partnership target in the rapidly evolving market.

Polygon

Polygon is trending due to its strategic pivot towards becoming a foundational layer for payments and Real-World Assets, underpinned by recent acquisitions and record network usage driving increased token burns. Despite community frustration that its price hasn't fully reflected these developments, many are actively accumulating Polygon, citing its strong fundamentals and perceived undervaluation.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines (UMAC) is gaining significant attention after being named a top analyst pick and securing a new $2.1 million defense order, reinforcing its crucial role as a domestic drone component supplier for the Pentagon's "Drone Dominance" initiative, while its high-profile advisory board member also sparks community discussion around potential future contracts.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is actively discussed amidst its participation in the Pentagon's "Drone Dominance" program and a recent Asia-Pacific military drone order, with investors weighing the potential for substantial defense contracts against persistent concerns over stock volatility and the timing of major revenue announcements.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending as the company certified its financial controls are effective and does not expect to restate financials, easing concerns after a significant price drop related to an SEC probe and leadership changes. The community is sharply divided, with bulls seeing a deep value opportunity given strong growth in AI and cloud partnerships, while bears highlight ongoing credibility risks from the past issues.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid fresh positive news including its Huntington's disease trial approval and strong international Elevidys sales, sparking community debate over the significant undervaluation of its commercial gene therapy franchise and deep RNA pipeline ahead of upcoming earnings, especially with notable short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Makes New $4.42 Million Investment in Arcus Biosciences, Inc. $RCUS

Aberdeen Group plc bought a new stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities...

Arcus Biosciences (RCUS) to Release Quarterly Earnings on Tuesday

Arcus Biosciences (NYSE:RCUS) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...

Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Hold" at Wells Fargo & Company

Wells Fargo & Company lowered shares of Arcus Biosciences from a "strong-buy" rating to a "hold" rating in a report on Thursday...

Candriam S.C.A. Takes $5.15 Million Position in Arcus Biosciences, Inc. $RCUS

Candriam S.C.A. acquired a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the third quarter, according to the company in its most recent filing with the Securities...

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory...

GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales

Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.

Rapid Innovation is Reshaping Oncology: Stocks in Focus

Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.

Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Arcus Biosciences (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and...

Arcus Biosciences, Inc. (NYSE:RCUS) Sees Significant Increase in Short Interest

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling...

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.11	--	--	N/A
Q3 '25	-$1.31	-$1.27	3.05%	BEAT
Q2 '25	-$1.13	-$1.11	1.85%	BEAT
Q1 '25	-$1.03	-$1.14	-10.57%	MISSED
Q4 '24	-$1.25	-$1.03	17.52%	BEAT

RCUS
Arcus Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest RCUS News

RCUSArcus Biosciences Inc